The analysis showed that the treatment with TGF-β downregulated the expressions of E-cadherin with significant upregulation of mesenchymal markers (N-cadherin and Vimentin) in both androgen-dependent and androgen-independent PCa cell lines. The gene discussed is TGFB1; the disease is posterior cortical atrophy.